Nichi-Iko Set To Delist In March As Tamura Steps Down As CEO
Successor To Be Selected At Extraordinary General Meeting In February
Executive Summary
After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.